Posted by Michael Wonder on 30 Dec 2022
FDA approves once weekly Wegovy injection for the treatment of obesity in teens aged 12 years and older
24 December 2022 - New indication based on clinical trial that demonstrated a 16.1% reduction in body mass index (BMI) in teens with obesity treated with Wegovy (semaglutide) injection 2.4 mg compared to placebo (0.6% increase in BMI).
Novo Nordisk today announced that the US FDA has approved a new indication for Wegovy (semaglutide) injection 2.4 mg, making it the first and only prescription anti-obesity medicine for teens with once weekly dosing.
